Juvinelle

Dienogest/Estradiol valerate, the active ingredients in Juvinelle, are a combined estrogen‑progestogen oral contraceptive presented as tablets for oral use. They work by suppressing ovulation and stabilising the endometrium, thereby preventing pregnancy and helping to regulate the menstrual cycle in women of reproductive age.

GNH USA supplies Juvinelle as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this hormonal contraceptive. The company adheres to stringent quality standards and offers regulatory support for global distribution.

Juvinelle, a combined estrogen‑progestogen oral contraceptive, is used in hormonal management of reproductive health. - Prevention of pregnancy: provides reliable contraception by inhibiting ovulation. - Regulation of menstrual cycle: helps achieve more predictable bleeding patterns. - Endometriosis symptom control: reduces pelvic pain associated with endometriosis.

Like all hormonal contraceptives, Juvinelle may be associated with a range of adverse reactions.

Common Side Effects: - Nausea: mild stomach upset, especially during the first cycles. - Headache: tension‑type or migraine‑like headaches. - Breast tenderness: temporary swelling or discomfort. - Breakthrough bleeding: spotting between periods.

Serious or Rare Side Effects: - Venous thromboembolism: deep vein thrombosis or pulmonary embolism. - Hypertensive crisis: sudden high blood pressure episodes. - Liver dysfunction: jaundice or abnormal liver enzymes.

Before prescribing Juvinelle, clinicians should consider several safety precautions to minimise risk. - Contraindication: avoid use in women who are pregnant or breastfeeding. - Smoking: do not prescribe to smokers over 35 years of age due to increased cardiovascular risk. - Cardiovascular disease: assess history of thromboembolic disorders, hypertension, or coronary artery disease. - Liver disease: use with caution in patients with active liver disease or hepatic tumors. - Medication review: evaluate concomitant use of drugs that affect coagulation or hormone metabolism. - Store at ambient temperature: keep tablets below 25 °C in the original packaging, protected from moisture and light.

Juvinelle can interact with other medicines, altering its effectiveness or increasing adverse effects.

Major Interactions (Avoid): - Combined hormonal contraceptives with enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin): may reduce contraceptive efficacy. - Rifampicin or other potent CYP3A4 inducers: can markedly decrease hormone levels. - Anticoagulants (warfarin): may increase risk of thrombosis when combined with estrogen.

Moderate Interactions (Monitor Closely): - Antifungal agents (ketoconazole, itraconazole): may increase hormone concentrations. - St. John’s wort: may lower contraceptive effectiveness. - Selective serotonin reuptake inhibitors (SSRIs): may exacerbate mood changes or bleeding patterns.